Evidence map›Paper›PMID 40567998›Full record

ArticleOpen forum infectious diseases2025

Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024.

Emily LaVerriere, Sasha Behar, Cole Sher-Jan, Yan Mei Liang, Manish Sagar, John H Connor

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emily LaVerriereDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-4750-4199
Sasha BeharDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0005-8883-7327
Cole Sher-JanDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
Yan Mei LiangDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
Manish SagarDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-9803-6594
John H ConnorDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8867-7256

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmissionR01AI172843 · NIAID · BOSTON MEDICAL CENTER · PI SAGAR, MANISH · 2022 to 2025
$3.5M
Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chipR01HL157790 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CONNOR, JOHN H, COOKE, JOHN P · 2021 to 2024
$2.8M
NHLBI NIH HHS R01 HL157790NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI172843
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is one of the main seasonal respiratory pathogens in the United States. Although several RSV vaccines were recently approved, vaccination rates remain low. We analyzed RSV-positive nasopharyngeal swabs from Boston Medical Center in 2024 using amplicon-based whole genome sequencing. We found that >80% of the samples were RSV-B, representing a major switch from 2022, when Boston RSV samples were approximately 90% RSV-A. Forty-five of 48 RSV-B samples mapped into a single clade (B.D.E.1), though not a single source within it, suggesting that the predominance of RSV-B is multifactorial. We also found examples of highly related genomes, suggesting clustered transmission. Mutations associated with vaccine escape were not observed. Our work highlights the importance of genomic surveillance for respiratory pathogens to monitor transmission dynamics, such as the unexpected switch from RSV-A to RSV-B dominance, and to understand the epidemiological changes that may be associated with RSV interventions.

Indexed as

genomic epidemiologygenomic surveillanceMassachusettsrespiratory infectionsrespiratory syncytial virus

Identifiers

PMID40567998
PMCPMC12188213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.